Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method
Open Access
- 23 August 2020
- Vol. 25 (17), 3830
- https://doi.org/10.3390/molecules25173830
Abstract
The SARS-CoV-2 outbreak caused an unprecedented global public health threat, having a high transmission rate with currently no drugs or vaccines approved. An alternative powerful additional approach to counteract COVID-19 is in silico drug repurposing. The SARS-CoV-2 main protease is essential for viral replication and an attractive drug target. In this study, we used the virtual screening protocol with both long-range and short-range interactions to select candidate SARS-CoV-2 main protease inhibitors. First, the Informational spectrum method applied for small molecules was used for searching the Drugbank database and further followed by molecular docking. After in silico screening of drug space, we identified 57 drugs as potential SARS-CoV-2 main protease inhibitors that we propose for further experimental testing.This publication has 48 references indexed in Scilit:
- Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 ReplicationAntimicrobial Agents and Chemotherapy, 2016
- Small-Molecule Library Screening by Docking with PyRxPublished by Springer Science and Business Media LLC ,2014
- Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parametersJournal of Molecular Modeling, 2012
- Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretionActa Endocrinologica, 2011
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Prediction of drug–target interaction networks from the integration of chemical and genomic spacesBioinformatics, 2008
- Valence bond theory for chemical dynamicsJournal of Computational Chemistry, 2006
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- Synthesis and anti-HIV activity of pyrrolo-[1,2-d]-(1,4)-benzodiazepin-6-onesBioorganic & Medicinal Chemistry Letters, 1992
- Simple General-Model PseudopotentialPhysical Review Letters, 1972